For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 0 |
| Cost of revenues | - | - | - | 0 |
| Selling, general and administrative expenses | 751,998 | 783,640 | 798,253 | 690,094 |
| Gross loss | - | - | - | 0 |
| Research and development expenses | 33,100 | 29,058 | 29,890 | 33,276 |
| Stock-based compensation | 787,374 | 1,386,213 | 1,136,217 | 1,571,613 |
| Total operating expenses | 1,572,472 | 2,198,911 | 1,964,360 | 2,294,983 |
| Loss from operations | -1,572,472 | -2,198,911 | -1,964,360 | -2,294,983 |
| Interest income | 3,765 | 81,606 | 47,287 | 19,139 |
| Interest expense | 49,377 | 32,551 | 30,959 | 129,413 |
| Loss on impairment of equity investment | - | -652,979 | -54,235 | -44,917 |
| Operating sublease income | 12,000 | 45,156* | 29,680 | - |
| Gain (loss) on foreign exchange changes | -51,156 | -91,229 | -112,553 | 136,148 |
| Loss on investment in equity securities | -31,416 | -157,399* | - | - |
| Operating sublease income | - | - | - | 12,000 |
| Other income (expenses) | -1,281 | -10,156 | 2,194 | -7,180 |
| Total other income (expenses) | -117,465 | -817,552 | -118,586 | -14,223 |
| Loss before provision income tax | -1,689,937 | -3,016,463 | -2,082,946 | -2,309,206 |
| Provision for income tax expense (benefit) | - | 0 | 527 | 23,627 |
| Net loss | -1,689,937 | -3,016,463 | -2,083,473 | -2,332,833 |
| Net loss attributable to non-controlling interests | -129,695 | -249,469 | -41,010 | -75,811 |
| Net loss attributed to abvc and subsidiaries | -1,560,242 | -2,766,994 | -2,042,463 | -2,257,022 |
| Foreign currency translation adjustment | 12,048 | 554 | 3,236 | 39,640 |
| Comprehensive loss | -1,548,194 | -2,766,440 | -2,039,227 | -2,217,382 |
| Basic EPS | -0.06 | -0.138 | -0.09 | -0.13 |
| Diluted EPS | -0.06 | -0.138 | -0.09 | -0.13 |
| Basic Average Shares | 25,448,516 | 20,108,944* | 23,256,590 | 17,386,536 |
| Diluted Average Shares | 25,448,516 | 20,108,944* | 23,256,590 | 17,386,536 |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)